Literature DB >> 16414944

Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice.

Carlo Napolitano1, Silvia G Priori, Peter J Schwartz, Raffaella Bloise, Elena Ronchetti, Janni Nastoli, Georgia Bottelli, Marina Cerrone, Sergio Leonardi.   

Abstract

CONTEXT: In long QT syndrome (LQTS), disease severity and response to therapy vary according to the genetic loci. There exists a critical need to devise strategies to expedite genetic analysis.
OBJECTIVE: To perform genetic screening in patients with LQTS to determine the yield of genetic testing, as well as the type and the prevalence of mutations. DESIGN, PATIENTS, AND
SETTING: We investigated whether the detection of a set of frequently mutated codons in the KCNQ1, KCNH2, and SCN5A genes may translate in a novel strategy for rapid efficient genetic testing of 430 consecutive patients referred to our center between June 1996 and June 2004. The entire coding regions of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 were screened by denaturing high-performance liquid chromatography and DNA sequencing. The frequency and the type of mutations were defined to identify a set of recurring mutations. A separate cohort of 75 consecutive probands was used as a validation group to quantify prospectively the prevalence of the recurring mutations identified in the primary LQTS population. MAIN OUTCOME MEASURES: Development of a novel approach to LQTS genotyping.
RESULTS: We identified 235 different mutations, 138 of which were novel, in 310 (72%) of 430 probands (49% KCNQ1, 39% KCNH2, 10% SCN5A, 1.7% KCNE1, and 0.7% KCNE2). Fifty-eight percent of probands carried nonprivate mutations in 64 codons of KCNQ1, KCNH2, and SCN5A genes. A similar occurrence of mutations at these codons (52%) was confirmed in the prospective cohort of 75 probands and in previously published LQTS cohorts.
CONCLUSIONS: We have developed an approach to improve the efficiency of genetic screening for LQTS. This novel method may facilitate wider access to genotyping resulting in better risk stratification and treatment of LQTS patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16414944     DOI: 10.1001/jama.294.23.2975

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  145 in total

Review 1.  HERG potassium channel regulation by the N-terminal eag domain.

Authors:  Ahleah S Gustina; Matthew C Trudeau
Journal:  Cell Signal       Date:  2012-04-13       Impact factor: 4.315

2.  Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.

Authors:  Matthew R Stump; Qiuming Gong; Zhengfeng Zhou
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

3.  Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation.

Authors:  Alon Barsheshet; Arthur J Moss; Scott McNitt; Slava Polonsky; Coeli M Lopes; Wojciech Zareba; Jennifer L Robinson; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Jeffrey A Towbin; G Michael Vincent; Ming Qi; Ilan Goldenberg
Journal:  Circ Cardiovasc Genet       Date:  2011-08-10

Review 4.  The molecular autopsy: should the evaluation continue after the funeral?

Authors:  David J Tester; Michael J Ackerman
Journal:  Pediatr Cardiol       Date:  2012-02-04       Impact factor: 1.655

5.  Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome.

Authors:  Qiuming Gong; Matthew R Stump; Zhengfeng Zhou
Journal:  J Mol Cell Cardiol       Date:  2010-10-28       Impact factor: 5.000

6.  Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome.

Authors:  Qiuming Gong; Li Zhang; G Michael Vincent; Benjamin D Horne; Zhengfeng Zhou
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  High-risk long QT syndrome mutations in the Kv7.1 (KCNQ1) pore disrupt the molecular basis for rapid K(+) permeation.

Authors:  Don E Burgess; Daniel C Bartos; Allison R Reloj; Kenneth S Campbell; Jonathan N Johnson; David J Tester; Michael J Ackerman; Véronique Fressart; Isabelle Denjoy; Pascale Guicheney; Arthur J Moss; Seiko Ohno; Minoru Horie; Brian P Delisle
Journal:  Biochemistry       Date:  2012-11-02       Impact factor: 3.162

8.  The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.

Authors:  Naomasa Makita; Elijah Behr; Wataru Shimizu; Minoru Horie; Akihiko Sunami; Lia Crotti; Eric Schulze-Bahr; Shigetomo Fukuhara; Naoki Mochizuki; Takeru Makiyama; Hideki Itoh; Michael Christiansen; Pascal McKeown; Koji Miyamoto; Shiro Kamakura; Hiroyuki Tsutsui; Peter J Schwartz; Alfred L George; Dan M Roden
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

Review 9.  From Genotype to Phenotype.

Authors:  Michael Mackley; Karen McGuire; Jenny Taylor; Hugh Watkins; Elizabeth Ormondroyd
Journal:  Circ Genom Precis Med       Date:  2018-10

Review 10.  Genetics of long QT syndrome.

Authors:  David J Tester; Michael J Ackerman
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.